We focus on
BUILDING A
BRIGHTER FUTURE

Bringing life-saving medicines answering high unmet medical needs and rare diseases through a bespoke organisation tailored to patient’s needs.

SERB is committed to bringing further innovative solutions into the market by accelerating our acquisitions and enhancing our R&D pipeline.

SERB has recently acquired BTG Specialty Pharmaceuticals business specialized in rescue medicines including antidotes counteracting certain snake venoms and certain toxicity associated with some heart and cancer medications, creating a global and leading platform in Critical Care and Rare Diseases.

Visit the BTG Specialty Website

In 2020, SERB has strengthened its neurology and rare diseases portfolio with the strategic acquisition of Veriton Pharma, specialised in the development of licensed and unlicensed medicines for patients with neurological conditions and metabolic disorders.

Visit the VERITON PHARMA Website